At present, Alzheimer's disease is detected mainly using psychological tests, which can only confirm the disease in its more advanced phases. Therefore, bioanalytical possibilities for detecting this disease earlier are being investigated. To date, the results of analyses, which focus mainly on the study of lipids and proteins either in cerebrospinal fluid or much less often in blood plasma, do not provide satisfactory results. In addition, cerebrospinal fluid sampling is uncomfortable for the patients and involves many health risks. In this work, we deal with proteomic analysis using Matrix-Assisted Laser Desorption/Ionisation-Time of Flight and Liquid Chromatography coupled to tandem Mass Spectrometry of blood plasma with a focus on various ways of preanalytical sample treatments. This should lead to results improvement and facilitate the subsequent evaluation using principal component analysis and partial least squares discriminant analysis. The obtained results indicate the direction of further research, namely the study of interactions between proteins and lipids contained in blood plasma. These substances may be regarded as potential biomarkers allowing for the diagnosis of Alzheimer ́s disease even in its early stages.

• MeSH
• Alzheimerova nemoc * krev   diagnóza   MeSH
• biologické markery krev   MeSH
• chromatografie kapalinová metody   MeSH
• krevní plazma chemie   MeSH
• krevní proteiny analýza   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lipidy krev   MeSH
• metabolismus lipidů MeSH
• proteomika metody   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• spektrometrie hmotnostní - ionizace laserem za účasti matrice metody   MeSH
• tandemová hmotnostní spektrometrie metody   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

Alzheimerova choroba je chronické neurodegenerativní onemocnění a je nejčastější příčinou demence ve světě. Rizikovou skupinou tohoto onemocnění jsou lidé ve věku nad 60 let, přičemž ne vždy má počáteční stadium onemocnění jasně zřetelné příznaky. Z tohoto důvodu je stále důležitým krokem k léčbě, nebo alespoň k zpomalení průběhu onemocnění, včasná a přesná diagnostika.

Alzheimer's disease is a chronic neurodegenerative disease and is the most common cause of dementia in the world. People at the age of 60 are a risk group for this disease, and the initial stage of the disease does not always have clear symptoms. For this reason, early and accurate diagnosis is still an important step to treat, or at least slow down the course of the disease.